ANAB · Insider Trading
AnaptysBio, Inc. Common Stock
Every open-market purchase and sale reported by ANAB officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Hollings Renton | Director | MIXED | — | −$159.22K |
| 2026-09-17 | John A Orwin | Director | M | +1,300 | — |
| 2026-08-07 | Daniel Faga | President, CEO | A | +53,334 deriv. | — |
| 2026-08-07 | Paul F. Lizzul | Chief Medical Officer | A | +16,667 deriv. | — |
| 2026-08-07 | Daniel Faga | President, CEO | A | +53,334 deriv. | — |
| 2026-08-07 | Paul F. Lizzul | Chief Medical Officer | A | +16,667 deriv. | — |
| 2026-06-17 | John A Orwin | Director | M | +6,030 | — |
| 2026-06-17 | Hollings Renton | Director | M | +6,030 | — |
| 2026-06-17 | John P. Schmid | Director | M | +6,030 | — |
| 2026-05-13 | Owen Hughes | Director | A | +11,250 deriv. | — |
| 2026-05-13 | Christopher M. Murphy | Chief Financial Officer | A | +25,765 deriv. | — |
| 2026-04-29 | Susannah Gray | Director | A | +11,250 deriv. | — |
| 2026-04-23 | Daniel Faga | President, CEO | D | −11,000 deriv. | — |
| 2026-04-22 | John A Orwin | Director | MIXED | — | — |
| 2026-04-22 | John P. Schmid | Director | MIXED | — | — |
| 2026-04-22 | Daniel Faga | President, CEO | MIXED | — | — |
| 2026-04-22 | Hollings Renton | Director | MIXED | — | — |
| 2026-04-01 | John P. Schmid | Director | Sell | −20,645 | −$1.16M |
| 2026-03-27 | Daniel Faga | President, CEO | MIXED | +16,621 | −$1.09M |
| 2026-02-13 | Eric J Loumeau | CHIEF LEGAL OFFICER | MIXED | — | −$243.00K |
| 2026-01-16 | Magda Marquet | Director | MIXED | — | −$243.32K |
| 2026-01-09 | Daniel Faga | President, CEO | MIXED | +12,557 | −$638.50K |
| 2026-01-09 | Eric J Loumeau | CHIEF LEGAL OFFICER | MIXED | +3,678 | −$98.81K |
| 2026-01-09 | Dennis Mulroy | CHIEF FINANCIAL OFFICER | MIXED | +4,185 | −$112.45K |
| 2026-01-09 | Paul F. Lizzul | Chief Medical Officer | MIXED | +4,875 | −$163.19K |
| 2026-01-08 | Rita Jain | Director | A | +9,500 deriv. | — |
| 2026-01-08 | John A Orwin | Director | A | +14,250 deriv. | — |
| 2026-01-08 | Paul F. Lizzul | Chief Medical Officer | MIXED | +3,910 | −$100.82K |
| 2026-01-08 | Dennis M Fenton | Director | A | +9,500 deriv. | — |
| 2026-01-08 | Hollings Renton | Director | A | +9,500 deriv. | — |
| 2026-01-08 | J. Anthony Ware | Director | A | +9,500 deriv. | — |
| 2026-01-08 | Magda Marquet | Director | A | +9,500 deriv. | — |
| 2026-01-08 | Eric J Loumeau | CHIEF LEGAL OFFICER | MIXED | −4,094 | −$439.20K |
| 2026-01-08 | John P. Schmid | Director | A | +9,500 deriv. | — |
| 2026-01-08 | Daniel Faga | President, CEO | MIXED | +8,648 | −$415.10K |
| 2026-01-08 | Dennis Mulroy | CHIEF FINANCIAL OFFICER | MIXED | +3,337 | −$86.07K |
| 2026-01-06 | Daniel Faga | President, CEO | MIXED | +19,368 | −$662.27K |
| 2026-01-06 | Dennis Mulroy | CHIEF FINANCIAL OFFICER | MIXED | +4,929 | −$145.48K |
| 2026-01-06 | Paul F. Lizzul | Chief Medical Officer | MIXED | +6,336 | −$182.51K |
| 2026-01-06 | Eric J Loumeau | CHIEF LEGAL OFFICER | MIXED | +4,304 | −$129.04K |
| 2025-12-23 | J. Anthony Ware | Director | Sell | −3,900 | −$193.34K |
| 2025-12-23 | Eric J Loumeau | CHIEF LEGAL OFFICER | MIXED | — | −$369.80K |
| 2025-12-23 | John P. Schmid | Director | J | −11,068 | −$564.47K |
| 2025-12-23 | Paul F. Lizzul | Chief Medical Officer | MIXED | — | −$47.25K |
| 2025-12-23 | Dennis Mulroy | CHIEF FINANCIAL OFFICER | MIXED | — | −$298.40K |
| 2025-12-18 | Dennis Mulroy | CHIEF FINANCIAL OFFICER | MIXED | −5,725 | −$503.73K |
| 2025-12-18 | Eric J Loumeau | CHIEF LEGAL OFFICER | MIXED | −141 | −$665.93K |
| 2025-10-01 | Eric J Loumeau | CHIEF LEGAL OFFICER | MIXED | −3,240 | −$168.86K |
| 2025-09-17 | John A Orwin | Director | M | +1,300 | — |
| 2025-08-12 | Hollings Renton | Director | MIXED | — | −$129.81K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| EcoR1 Capital, LLC | Director | 7,880,094 | $384.31M |
| Daniel Faga | President, CEO | 505,862 | $24.67M |
| Paul F. Lizzul | Chief Medical Officer | 42,088 | $2.05M |
| John P. Schmid | Director | 37,652 | $1.84M |
| Dennis Mulroy | CHIEF FINANCIAL OFFICER | 24,367 | $1.19M |
| Eric J Loumeau | CHIEF LEGAL OFFICER | 22,835 | $1.11M |
| John A Orwin | Director | 17,995 | $877.62K |
| Rita Jain | Director | 11,864 | $578.61K |
| Magda Marquet | Director | 11,640 | $567.68K |
| Hollings Renton | Director | 10,995 | $536.23K |
| J. Anthony Ware | Director | 9,630 | $469.66K |
| Dennis M Fenton | Director | 4,965 | $242.14K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ANAB quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.